



FY2010 1st Quarter Business Results

(FY2010 ending March 31, 2010)


August 4, 2009
IR & Corporate Communication Div.

Sysmex Corporation

1st Quarter Financial Results

(For the years ended March 31)

(In billions of JPY)



■ Sales ● Operating Income
● Ordinary Income ● Net Income

Exchange rate in the preceding 1Q report;
1US\$=¥104.6, 1EUR=¥163.4

Exchange rate in this 1Q report;
1US\$=¥ 97.3, 1EUR=¥132.6

(In billions of JPY)

	FY2010 1Q	Ratio	FY2009 1Q	Ratio	% over a Year Earlier
Net sales	24.9	100%	26.1	100%	95.5%
Operating income	1.6	6.5%	2.0	7.7%	81.0%
Ordinary income	1.7	7.1%	2.7	10.6%	64.0%
Net income	1.1	4.5%	1.4	5.4%	79.8%

● Targets being achieved almost to schedule

- ▶ On the mid-term plan, setting decreases in annual sales and income of FY2010 due to the impact of yen's appreciation
Planned exchange rate: 1US\$=¥95、1EUR=¥125
- ▶ Applying exchange rates of previous year in comparison with the same period last year: Net sales, 107.2%; Operating income, 141.2%

● Slight impact of economic downturn

● VS. previous year in local currency

- ▶ Net sales: Increased in Europe, China, and AP; Flat in the Americas
- ▶ Operating income: Increased in the Americas, Europe, and China; Flat in AP

* Capital expenditure; ¥0.5billion Depreciation and amortization; ¥1.5billion R&D expenditure; ¥2.5billion



Breakdown of Net Sales and Operating Income

(For the years ended March 31)

(In billions of JPY)

Net Sales

Operating Income



Topics in 1st Quarter

New Products

- Line-up of reagents for HISCL-2000i in the immunochemistry field enriched
Reagents for hepatitis B and cancer tumor will be launched

Affiliates and Offices

- Direct sales and support in Benelux (Belgium, the Netherlands and Luxembourg) started (in April)
By new subsidiaries in Belgium and the Netherlands
- Educational center established in Sysmex CZ (Czech Republic)

Others

- Kids Park, a company nursery, opened
- Production of simplified influenza test kits increased due to new influenza pandemic

Geographic Segment Information: Americas

(For the years ended March 31)

(In billions of JPY)

(In billions of JPY)	FY2010 1Q	FY2009 1Q	% over a Year Earlier
Net sales	5.4	5.9	92.6%
Operating income	0.26	0.21	122.9%


* On a local currency basis: Net sales, 99.5%; Operating income, 125.9%

- Hematology business is good performance in the US, but income decreased in the Americas.

- ▶ Sales in the US soared according to increased market share.
- ▶ Sales in Mexico and Canada decreased due to the impact of swine flu, such as postponed budgeting.

(There were a large number of tenders in Mexico in the 1st quarter of previous year.)

- Operating margin recovered because of increased direct sales ratio and increased ratio of reagent and after-sales support to total sales.



Geographic Segment Information: Europe

(For the years ended March 31)

(In billions of JPY)

(In billions of JPY)	FY2010 1Q	FY2009 1Q	% over a Year Earlier
Net sales	9.0	9.8	91.9%
Operating income	1.1	1.4	85.3%


* On a local currency basis: Net sales, 113.3%; Operating income, 104.9%

- Sales and income increased on a local currency basis, but decreased in yen due to the impact of yen's appreciation.

- ▶ Sales increased because of the direct sales in France and strengthened support from distributors in the Middle East.
- ▶ Benelux, where direct sales started in April, contributed to the increase of sales.

SG&A expenses; Increased in cost of labor and goodwill

- ▶ UK increased sales on a sterling basis, but decreased in yen due to FX impact (sterling depreciation).



* Reform accounting standards for lease

Geographic Segment Information: China


(For the years ended March 31)

(In billions of JPY)

(In billions of JPY)	FY2010 1Q	FY2009 1Q	% over a Year Earlier
Net sales	2.1	1.8	113.7%
Operating income	0.48	0.19	246.4%

* On a local currency basis: Net sales, 119.9%; Operating income, 260.4%

- Both sales and operating income grew over 10%.
- Sales in the hematology and hemostasis fields soared.
 - ▶ Sales of high-end models and system products in the hematology field increased through direct business with customers.
 - ▶ Growth in the hemostasis field was steady because of the active use of distributors.
 - ▶ Tenders in the low-end market for hematology products remained inactive.
- Operating margin recovered due to an increase in the reagent sales to total sales ratio.
- Chinese government released medical reform plan; Investments into medical infrastructure.



Geographic Segment Information: AP

<Excluding Korea, Taiwan, and Mongolia> (For the years ended March 31)

(In billions of JPY)

(In billions of JPY)	FY2010 1Q	FY2009 1Q	% over a Year Earlier
Net sales	1.1	1.2	92.3%
Operating income	0.16	0.20	80.8%

* On a local currency basis: Net sales, 106.8%; Operating income, 94.3%


- Growth in the hematology field in Southeast Asia was steady.

- ▶ A system product was introduced into the largest hospital in the Philippines

- Some governmental tenders were postponed in Malaysia.

(There were a large number of tenders in AP in the 1st quarter of previous year.)


- Operating income decreased due to the impact of yen's appreciation.



Geographic Segment Information: Japan

<Including Korea, Taiwan, and Mongolia> (For the years ended March 31)

(In billions of JPY)		FY2010 1Q	FY2009 1Q	% over a Year Earlier
Net sales		13.3	15.2	87.6%
Sales to customers	Japan	6.7	6.8	98.4%
	Korea, Taiwan, and Mongolia	0.45	0.44	102.4%
Intra-area Transfer		6.1	7.8	77.3%
Operating income		Δ0.47	0.73	-



Sales to customers (Japan)

- ▶ Growth in the hematology field was steady because of the solutions offered.
- ▶ Sales of POCs (simplified test kits) increased because of the new influenza pandemic.
- ▶ Sales in immunochemistry and clinical chemistry decreased.

Intra-area Transfer

- ▶ Exports to affiliates decreased due to the impact of yen's appreciation.

Operating income decreased due to the impact of yen's appreciation.

- ▶ Operating income slightly fluctuated upper than estimated because of controlling SG&A expenses.

Intra-area Transfer: Exports to group affiliates
 Sales to customers: Korea, Taiwan and Mongolia
 Sales to customers: Japan
 Operating Income

Consolidated Earnings Forecast (Not revised since May 2009)

(For the years ended March 31)

FY2009 Consolidated Earnings Forecast


- Net sales: ¥116 billion
- Operating income: ¥13 billion
- Net income: ¥8.1 billion
- Operating margin: 11.2 %
- Net income margin: 7.0 %

Investment plan

- Capital Expenditure: ¥6 billion
- Depreciation and amortization: ¥7.5 billion
- R&D Expenditure: ¥10.8 billion

(In billions of JPY)

Planned exchange rate: 1 US \$ = ¥ 95 1 EUR = ¥ 125





We Believe the Possibilities.

Sysmex Corporation

<Contact>

IR & Corporate Communication Div.

Phone: +81-78-265-0500

Email: info@sysmex.co.jp

URL www.sysmex.co.jp